Want to see KR:004310 full AI Analyst Report?
Top Page
Hyundai Pharmaceutical Co., Ltd.
(004310)
Select Model
Select Model
Rating:52Neutral
Price Target:
₩6,919.00
Action:N/A
Date:10/28/26
The score is primarily supported by improving financial performance (revenue rebound, return to profitability, and a stronger balance sheet), but is held back by weak cash-flow reliability, bearish technical momentum (below key moving averages with negative MACD), and an expensive valuation (high P/E with low dividend yield).
Positive Factors
Revenue rebound
The strong TTM revenue rebound indicates improving demand and commercial execution after weaker periods. Continued top-line expansion would provide a broader base for operating leverage, product investment, and improved earnings durability over the next several quarters.
Negative Factors
Thin and uneven margins
Low single-digit margins leave limited protection against operating setbacks and make earnings sensitive to changes in revenue or expenses. The history of choppy results and prior losses also indicates that the recent recovery has not yet demonstrated consistent, high-quality profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The strong TTM revenue rebound indicates improving demand and commercial execution after weaker periods. Continued top-line expansion would provide a broader base for operating leverage, product investment, and improved earnings durability over the next several quarters.
Read all positive factors
Hyundai Pharmaceutical Co., Ltd. (004310) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩212.70B
Dividend Yield0.44%
Average Volume (3M)2.56M
Price to Earnings (P/E)59.8
Beta (1Y)0.59
Revenue Growth11.35%
EPS Growth204.54%
CountryKR
Employees399
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)120.84
Shares Outstanding32,000,000
10 Day Avg. Volume1,032,861
30 Day Avg. Volume2,563,738
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.50
P/FCF Ratio-20.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hyundai Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Seoul, South Korea, Hyundai Pharmaceutical Co., Ltd. is an international manufacturer and distributor of a diverse portfolio that includes pharmaceutical products, health food beverages, and medical equipment. The company's extens...
Hyundai Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
72
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 207.04B | 191.79B | 175.74B | 180.76B | 162.69B | 139.80B |
| Gross Profit | 73.63B | 78.23B | 73.37B | 75.24B | 68.84B | 56.31B |
| EBITDA | 10.38B | 7.58B | 3.94B | 13.21B | 10.04B | 670.96M |
| Net Income | 3.61B | 2.52B | -574.89M | 6.12B | -164.58M | -3.17B |
Balance Sheet | ||||||
| Total Assets | 227.47B | 166.90B | 156.40B | 154.63B | 181.16B | 163.86B |
| Cash, Cash Equivalents and Short-Term Investments | 22.72B | 2.50B | 10.55B | 18.64B | 34.53B | 22.21B |
| Total Debt | 49.54B | 50.06B | 48.08B | 39.20B | 39.44B | 29.84B |
| Total Liabilities | 97.36B | 84.80B | 77.32B | 69.63B | 94.60B | 77.26B |
| Stockholders Equity | 129.12B | 82.10B | 79.07B | 84.66B | 86.56B | 86.60B |
Cash Flow | ||||||
| Free Cash Flow | 6.92B | -4.73B | -13.56B | -10.65B | 5.04B | -1.68B |
| Operating Cash Flow | 10.27B | -123.29M | -2.37B | -4.55B | 11.62B | 5.13B |
| Investing Cash Flow | -18.82B | -8.37B | -9.66B | -3.09B | -9.99B | -27.75M |
| Financing Cash Flow | 18.84B | 720.97M | 6.10B | -6.43B | 7.01B | 3.25B |
Hyundai Pharmaceutical Co., Ltd. Technical Analysis
Negative
―
Price Trends
7842.20
Negative
6995.40
Negative
8318.16
Negative
Market Momentum
-387.61
Positive
36.79
Neutral
14.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:004310, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 7597.50, equal to the 50-day MA of 7842.20, and equal to the 200-day MA of 8318.16, indicating a bearish trend. The MACD of -387.61 indicates Positive momentum. The RSI at 36.79 is Neutral, neither overbought nor oversold. The STOCH value of 14.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:004310.
Hyundai Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₩243.17B | 3.39 | ― | 3.64% | 4.13% | 116.32% | |
66 Neutral | ₩225.55B | 10.30 | ― | 4.16% | 0.28% | 16.80% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₩212.70B | 59.83 | ― | 0.44% | 11.35% | 204.54% | |
50 Neutral | ₩169.19B | 63.80 | ― | 3.22% | 1.83% | -67.89% | |
44 Neutral | ₩177.54B | -5.13 | ― | 1.41% | -4.45% | -250.71% | |
40 Underperform | ₩173.93B | -28.12 | ― | ― | 0.60% | -6964.46% |
* General Sector Average
KR:004310
Hyundai Pharmaceutical Co., Ltd.
6,880.00
3,159.39
84.92%
KR:003220
Daewon Pharmaceutical Co., Ltd
7,760.00
-5,120.31
-39.75%
KR:003520
YUNGJIN PHARM. CO. LTD
951.00
-1,089.00
-53.38%
KR:005500
Samjin Pharmaceutical Co., Ltd.
19,240.00
174.53
0.92%
KR:033270
KOREA UNITED PHARM, INC.
16,760.00
-1,833.09
-9.86%
KR:102460
Reyon Pharmaceutical Co., Ltd.
9,680.00
-1,320.00
-12.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.